Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

CRISPR Therapeutics Company

CRSP
CH0334081137
A2AT0Z

Price

46.85
Today +/-
+1.33
Today %
+3.17 %
P

CRISPR Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CRISPR Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CRISPR Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CRISPR Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CRISPR Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CRISPR Therapeutics Stock Price History

DateCRISPR Therapeutics Price
10/11/202446.85 undefined
10/10/202445.39 undefined
10/9/202445.40 undefined
10/8/202445.20 undefined
10/7/202445.49 undefined
10/4/202445.37 undefined
10/3/202444.90 undefined
10/2/202445.71 undefined
10/1/202445.58 undefined
9/30/202446.98 undefined
9/27/202447.32 undefined
9/26/202446.49 undefined
9/25/202445.92 undefined
9/24/202446.79 undefined
9/23/202446.74 undefined
9/20/202448.18 undefined
9/19/202449.49 undefined
9/18/202449.59 undefined
9/17/202449.87 undefined
9/16/202447.74 undefined

CRISPR Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CRISPR Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CRISPR Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CRISPR Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CRISPR Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CRISPR Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CRISPR Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CRISPR Therapeutics’s growth potential.

CRISPR Therapeutics Revenue, EBIT and net profit per share

DateCRISPR Therapeutics RevenueCRISPR Therapeutics EBITCRISPR Therapeutics Net Income
2030e8.65 B undefined3.77 B undefined3.37 B undefined
2029e3.6 B undefined2.12 B undefined1.03 B undefined
2028e2.15 B undefined420.38 M undefined414.77 M undefined
2027e1.46 B undefined60.91 M undefined82.63 M undefined
2026e806.66 M undefined-206.59 M undefined-176.63 M undefined
2025e293.89 M undefined-469.99 M undefined-430.54 M undefined
2024e50.74 M undefined-568.39 M undefined-500.1 M undefined
2023371.21 M undefined-222.54 M undefined-153.61 M undefined
20221.2 M undefined-673.2 M undefined-650.2 M undefined
2021915 M undefined373.5 M undefined377.7 M undefined
2020700,000 undefined-354.4 M undefined-348.9 M undefined
2019289.6 M undefined46.7 M undefined66.9 M undefined
20183.1 M undefined-158.9 M undefined-165 M undefined
201741 M undefined-64.6 M undefined-68.4 M undefined
20165.2 M undefined-68.1 M undefined-23.2 M undefined
2015200,000 undefined-25.7 M undefined-25.5 M undefined
20140 undefined-6.6 M undefined-7 M undefined

CRISPR Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000.010.0400.2900.9200.370.050.290.811.462.153.68.65
---720.00-92.689,533.33---99.8937,000.00-86.52486.00175.0981.1447.2667.49140.13
-----------------
00000000000000000
-0.01-0.03-0.07-0.06-0.160.05-0.350.37-0.67-0.22-0.57-0.47-0.210.060.422.123.77
---1,360.00-156.10-5,266.6715.92-40.77-67,300.00-59.84-1,136.00-160.07-25.564.1119.5358.9343.59
-0.01-0.03-0.02-0.07-0.170.07-0.350.38-0.65-0.15-0.5-0.43-0.180.080.411.033.37
-257.14-8.00195.65142.65-140.00-627.27-208.33-272.41-76.46226.80-14.00-59.07-146.59404.88147.83228.36
39.739.712.340.14856.965.980.477.779.220000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The CRISPR Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CRISPR Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2014201520162017201820192020202120222023
                   
00.160.320.240.460.941.692.381.821.69
00.33.22.60.10.10.10.30200
0000000000
0000000000
00.51.569.743.726.138.137.714.39
00.160.320.250.470.991.722.421.851.91
01.32118.918.572.893312320.6305.94
0000000053.11.97
0000000000
50050040030030020020010010016
0000000000
0.10.83.33.83.86.118.122.216.313.57
0.62.624.72322.679.1111.3334.3390.1321.49
00.160.340.270.491.071.832.752.242.23
                   
6.464.71.21.21.61.82.32.42.42.5
000.290.310.681.162.242.62.732.88
-8.4-33.9-57.1-125.4-291.6-224.7-573.6-195.9-846.1-999.7
000000-0.1-5.1-15.61.91
0000000000
-00.040.230.190.390.941.662.41.881.88
0.21.64.61.65.15.99.114.827.438.15
1.98.416.311.420.938.765.1103.293.560.96
00.11.11.51.812.5201.90.29.68
0000000000
0000000000
2.110.12214.527.857.194.2119.9121.1108.79
038.300000000
0000000000
0.175.590.16969.170.269.5232.5246.5237.98
0.1113.890.16969.170.269.5232.5246.5237.98
2.2123.9112.183.596.9127.3163.7352.4367.6346.77
00.160.340.270.491.071.832.752.242.23
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CRISPR Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CRISPR Therapeutics's financial health and stability.

Assets

CRISPR Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CRISPR Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CRISPR Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CRISPR Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-6-25-23-68-16566-348377-650-153
0003349182419
0000000000
1811-2510-48332619-193
17-23398977133218208148
0000000000
0000000000
-459-55-70-9656-238539-495-260
0-1-3-7-2-6-18-81-37-11
0-131-8-21-541-1,035-258374
0034008-522-953-221386
0000000000
038350000000
0.010.060.1200.320.431.020.250.040.06
0.010.10.1800.320.431.020.250.040.06
00330000000
0000000000
0154159-75216489236-245-715177
-4.858.2-58.3-77.9-9950-256.8457.3-532.9-272.35
0000000000

CRISPR Therapeutics stock margins

The CRISPR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CRISPR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CRISPR Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CRISPR Therapeutics's sales revenue. A higher gross margin percentage indicates that the CRISPR Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CRISPR Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CRISPR Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CRISPR Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CRISPR Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CRISPR Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CRISPR Therapeutics Margin History

CRISPR Therapeutics Gross marginCRISPR Therapeutics Profit marginCRISPR Therapeutics EBIT marginCRISPR Therapeutics Profit margin
2030e0 %43.58 %38.97 %
2029e0 %58.91 %28.5 %
2028e0 %19.55 %19.29 %
2027e0 %4.17 %5.66 %
2026e0 %-25.61 %-21.9 %
2025e0 %-159.92 %-146.5 %
2024e0 %-1,120.21 %-985.62 %
20230 %-59.95 %-41.38 %
20220 %-56,100 %-54,183.33 %
20210 %40.82 %41.28 %
20200 %-50,628.57 %-49,842.86 %
20190 %16.13 %23.1 %
20180 %-5,125.81 %-5,322.58 %
20170 %-157.56 %-166.83 %
20160 %-1,309.62 %-446.15 %
20150 %-12,850 %-12,750 %
20140 %0 %0 %

CRISPR Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The CRISPR Therapeutics earnings per share therefore indicates how much revenue CRISPR Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CRISPR Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CRISPR Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CRISPR Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CRISPR Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CRISPR Therapeutics Revenue, EBIT and net profit per share

DateCRISPR Therapeutics Sales per ShareCRISPR Therapeutics EBIT per shareCRISPR Therapeutics Earnings per Share
2030e101.54 undefined0 undefined39.57 undefined
2029e42.29 undefined0 undefined12.05 undefined
2028e25.24 undefined0 undefined4.87 undefined
2027e17.15 undefined0 undefined0.97 undefined
2026e9.47 undefined0 undefined-2.07 undefined
2025e3.45 undefined0 undefined-5.06 undefined
2024e0.6 undefined0 undefined-5.87 undefined
20234.69 undefined-2.81 undefined-1.94 undefined
20220.02 undefined-8.66 undefined-8.37 undefined
202111.38 undefined4.65 undefined4.7 undefined
20200.01 undefined-5.38 undefined-5.29 undefined
20195.09 undefined0.82 undefined1.18 undefined
20180.06 undefined-3.31 undefined-3.44 undefined
20171.02 undefined-1.61 undefined-1.71 undefined
20160.42 undefined-5.54 undefined-1.89 undefined
20150.01 undefined-0.65 undefined-0.64 undefined
20140 undefined-0.17 undefined-0.18 undefined

CRISPR Therapeutics business model

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics is one of the most popular companies on Eulerpool.com.

CRISPR Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

CRISPR Therapeutics Revenue by Segment

Segmente20222021202020192018
Collaboration Revenue436,000 USD913.08 M USD---
Technology Service----34.9 M USD
Grant Revenue762,000 USD1.88 M USD176,000 USD--
License and Service---500,000 USD600,000 USD
Collaboration revenue--543,000 USD--

CRISPR Therapeutics SWOT Analysis

Strengths

1. Strong Intellectual Property: CRISPR Therapeutics AG possesses a robust portfolio of patents related to CRISPR gene-editing technology, providing them with a competitive advantage in the market.

2. Cutting-Edge Technology: The company specializes in developing innovative gene therapies utilizing CRISPR-Cas9, a revolutionary genome editing technique with immense potential for treating genetic diseases.

3. Strategic Partnerships: CRISPR Therapeutics AG has established collaborations with leading pharmaceutical companies, which strengthens their research capabilities, expands their reach, and facilitates licensing opportunities.

Weaknesses

1. Limited Clinical Pipeline: Although CRISPR Therapeutics AG has several promising programs in preclinical and early clinical stages, their current pipeline of potential therapies is relatively small compared to some competitors.

2. Regulatory Challenges: As with any novel therapeutic approach, CRISPR gene editing faces regulatory hurdles and ethical concerns, which may delay approval processes and affect market adoption.

Opportunities

1. Unmet Medical Needs: The increasing prevalence of genetic disorders combined with limited treatment options presents a significant opportunity for CRISPR Therapeutics AG to address unmet medical needs and create breakthrough therapies.

2. Expansion into New Indications: CRISPR gene editing has the potential to be applied beyond genetic diseases, such as cancer immunotherapies or agricultural advancements. CRISPR Therapeutics AG can explore these new indications to diversify their product portfolio.

Threats

1. Competition: CRISPR Therapeutics AG operates in a highly competitive landscape with other biotechnology companies also exploring gene-editing technologies. Increased competition may affect market share and limit pricing power.

2. Intellectual Property Disputes: There is ongoing litigation and disputes surrounding the intellectual property rights related to CRISPR-Cas9 technology, which may impact the exclusivity and commercialization opportunities for CRISPR Therapeutics AG.

CRISPR Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CRISPR Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

CRISPR Therapeutics shares outstanding

The number of shares was CRISPR Therapeutics in 2023 — This indicates how many shares 79.221 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CRISPR Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CRISPR Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CRISPR Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CRISPR Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for CRISPR Therapeutics.

CRISPR Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.55 -1.49  (4.06 %)2024 Q2
3/31/2024-1.36 -1.43  (-5.19 %)2024 Q1
12/31/2023-0.07 1.1  (1,592.54 %)2023 Q4
9/30/2023-1.99 -1.41  (29.14 %)2023 Q3
6/30/2023-2.16 -0.98  (54.63 %)2023 Q2
3/31/2023-1.74 -0.67  (61.43 %)2023 Q1
12/31/2022-2.35 -1.41  (39.87 %)2022 Q4
9/30/2022-2.34 -2.24  (4.11 %)2022 Q3
6/30/2022-2.27 -2.4  (-5.64 %)2022 Q2
3/31/2022-1.98 -2.32  (-17.46 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the CRISPR Therapeutics stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

36

👫 Social

72

🏛️ Governance

50

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CRISPR Therapeutics shareholders

%
Name
Stocks
Change
Date
9.65598 % Capital International Investors8,223,9942,089,5443/29/2024
9.57735 % ARK Investment Management LLC8,157,028-379,0763/31/2024
4.23997 % T. Rowe Price Investment Management, Inc.3,611,186-40,64712/31/2023
3.95651 % Nikko Asset Management Americas, Inc.3,369,762-95,70812/31/2023
3.83795 % Nikko Asset Management Co., Ltd.3,268,7853,268,7853/31/2024
2.67046 % BlackRock Institutional Trust Company, N.A.2,274,432-69,37212/31/2023
2.16023 % Fidelity Management & Research Company LLC1,839,871-217,54312/31/2023
2.05882 % State Street Global Advisors (US)1,753,497-131,47612/31/2023
1.86433 % New Enterprise Associates (NEA)1,587,854012/31/2023
1.84907 % The Vanguard Group, Inc.1,574,84951,92612/31/2023
1
2
3
4
5
...
10

CRISPR Therapeutics Executives and Management Board

Dr. Samarth Kulkarni44
CRISPR Therapeutics Chairman of the Board, Chief Executive Officer (since 2017)
Compensation 20.73 M
Dr. Phuong Morrow49
CRISPR Therapeutics Chief Medical Officer
Compensation 5.78 M
Mr. James Kasinger51
CRISPR Therapeutics General Counsel, Secretary
Compensation 3.3 M
Dr. Maria Fardis55
CRISPR Therapeutics Independent Director
Compensation 1.12 M
Mr. John Greene57
CRISPR Therapeutics Independent Director
Compensation 620,931
1
2
3

CRISPR Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
CureVac Stock
CureVac
SupplierCustomer0,810,840,700,850,93-
MaxCyte Stock
MaxCyte
SupplierCustomer0,630,150,630,86--
Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals
SupplierCustomer0,570,670,20-0,53-0,74-0,38
CryoPort Stock
CryoPort
SupplierCustomer0,260,610,850,880,700,56
Nkarta Stock
Nkarta
SupplierCustomer-0,030,15-0,430,190,91-
1

Most common questions regarding CRISPR Therapeutics

What values and corporate philosophy does CRISPR Therapeutics represent?

CRISPR Therapeutics AG is a leading biotechnology company known for its revolutionary gene-editing technology. The company's values lie in the belief that genetic diseases can be treated and cured using CRISPR-Cas9, a precise and efficient gene-editing tool. With a commitment to improving patients' lives, CRISPR Therapeutics AG aims to develop transformative therapies for multiple genetic disorders. Their corporate philosophy centers around innovation, dedication to scientific advancements, and collaboration with partners to ensure the rapid translation of their technology into potential treatments. Through their cutting-edge research and development, CRISPR Therapeutics AG strives to make significant contributions to the field of gene editing and ultimately bring hope to patients worldwide.

In which countries and regions is CRISPR Therapeutics primarily present?

CRISPR Therapeutics AG is primarily present in various countries and regions around the world. The company operates from its headquarters in Basel, Switzerland, providing its groundbreaking gene-editing technology globally. CRISPR Therapeutics AG has a strong presence in the United States, with research and development facilities located in Cambridge, Massachusetts. Additionally, the company has expanded its reach to other regions, including Europe and Asia. With its focus on developing transformative therapies using CRISPR-Cas9 gene-editing technology, CRISPR Therapeutics AG continues to collaborate with partners across the globe to bring innovative treatments to patients in need.

What significant milestones has the company CRISPR Therapeutics achieved?

CRISPR Therapeutics AG has reached several significant milestones in its journey. The company successfully initiated clinical trials for the treatment of beta-thalassemia and sickle cell disease using CRISPR-Cas9 gene editing technology. This groundbreaking approach holds great promise in revolutionizing the field of genetic medicine. Additionally, CRISPR Therapeutics AG entered into strategic collaborations with various pharmaceutical companies to develop novel therapeutics for a wide range of diseases. Moreover, the company obtained Fast Track Designation from the U.S. FDA for its CTX001 therapy, further validating its innovative approach and potential impact on patients' lives. CRISPR Therapeutics AG continues to make remarkable progress in advancing gene editing therapies for various genetic disorders.

What is the history and background of the company CRISPR Therapeutics?

CRISPR Therapeutics AG is a biopharmaceutical company headquartered in Switzerland. Founded in 2013, the company focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG aims to provide treatments for a wide range of diseases with unmet medical needs. Since its inception, CRISPR Therapeutics AG has made significant advancements in the field of gene editing. The company has forged numerous collaborations with leading pharmaceutical companies to accelerate the development and commercialization of potential therapies. With a robust pipeline and a team of dedicated scientists, CRISPR Therapeutics AG continues to drive innovation in the realm of precision medicine. As a leader in gene-editing technology, CRISPR Therapeutics AG remains committed to improving patients' lives through its groundbreaking research and development efforts.

Who are the main competitors of CRISPR Therapeutics in the market?

The main competitors of CRISPR Therapeutics AG in the market are Editas Medicine, Inc., Intellia Therapeutics, Inc., and Sangamo Therapeutics, Inc.

In which industries is CRISPR Therapeutics primarily active?

CRISPR Therapeutics AG is primarily active in the biotechnology industry.

What is the business model of CRISPR Therapeutics?

The business model of CRISPR Therapeutics AG is focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company aims to address a wide range of severe diseases by leveraging the potential of CRISPR technology to correct genetic defects. CRISPR Therapeutics AG collaborates with various partners to advance its pipeline of therapeutic candidates, spanning areas like hematology, oncology, ophthalmology, and regenerative medicine. Their goal is to bring novel and curative treatments to patients with unmet medical needs. CRISPR Therapeutics AG prioritizes innovation, strategic alliances, and continuous research to drive the advancement of gene-based therapies.

What is the P/E ratio of CRISPR Therapeutics 2024?

The CRISPR Therapeutics P/E ratio is -7.42.

What is the P/S ratio of CRISPR Therapeutics 2024?

The CRISPR Therapeutics P/S ratio is 73.15.

What is the Quality Investing of CRISPR Therapeutics?

The Quality Investing for CRISPR Therapeutics is 2/10.

What is the revenue of CRISPR Therapeutics 2024?

The expected CRISPR Therapeutics revenue is 50.74 M USD.

How high is the profit of CRISPR Therapeutics 2024?

The expected CRISPR Therapeutics profit is -500.1 M USD.

What is the business model of CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company focused on the discovery and development of therapies for genetic diseases. The company uses the innovative CRISPR/Cas9 technology to make specific changes in the human genome and treat hereditary diseases. Its business model is based on researching and applying this technology to develop therapeutics for genetic diseases. CRISPR Therapeutics has a wide pipeline of products at various stages of development, from preclinical to clinical phase III. The company has an exclusive license for the therapeutic use of CRISPR/Cas9 technology from the University of California, Berkeley and the Massachusetts Institute of Technology (MIT). It has also formed a strategic alliance with Vertex Pharmaceuticals to develop new therapies for lysosomal storage diseases. One of the key products being developed by CRISPR Therapeutics is CTX001, a gene therapy for the treatment of beta-thalassemia and sickle cell disease. This therapy uses CRISPR/Cas9 to modify the patient's blood stem cells to increase the production of fetal hemoglobin and replace the defective hemoglobin. CTX001 is currently in clinical phase III development and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing therapies for other genetic diseases such as hemophilia A, Duchenne muscular dystrophy, and cystic fibrosis. This is achieved by targeting disease-causing genes and using CRISPR/Cas9 to regulate gene expression. The company's business model also includes licensing its technology to other companies for the development of therapies for other diseases. It has partnered with Bayer to develop therapies for the treatment of blood and liver diseases. Overall, CRISPR Therapeutics has an innovative business model based on the use of CRISPR/Cas9 technology to make specific changes in the human genome and treat or cure genetic diseases. Through the development of CTX001 and other therapies, the company has significant potential to improve the lives of patients with genetic diseases.

What is the CRISPR Therapeutics dividend?

CRISPR Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does CRISPR Therapeutics pay dividends?

The dividend cannot currently be calculated for CRISPR Therapeutics or the company does not pay out a dividend.

What is the CRISPR Therapeutics ISIN?

The ISIN of CRISPR Therapeutics is CH0334081137.

What is the CRISPR Therapeutics WKN?

The WKN of CRISPR Therapeutics is A2AT0Z.

What is the CRISPR Therapeutics ticker?

The ticker of CRISPR Therapeutics is CRSP.

How much dividend does CRISPR Therapeutics pay?

Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CRISPR Therapeutics?

The current dividend yield of CRISPR Therapeutics is .

When does CRISPR Therapeutics pay dividends?

CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CRISPR Therapeutics?

CRISPR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CRISPR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CRISPR Therapeutics located?

CRISPR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CRISPR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CRISPR Therapeutics from 10/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/13/2024.

When did CRISPR Therapeutics pay the last dividend?

The last dividend was paid out on 10/13/2024.

What was the dividend of CRISPR Therapeutics in the year 2023?

In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.

In which currency does CRISPR Therapeutics pay out the dividend?

The dividends of CRISPR Therapeutics are distributed in USD.

All fundamentals about CRISPR Therapeutics

Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.